Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dacomitinib→

Dacomitinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1110813-31-4
Molecular formula
C24H25ClFN5O2
Molecular weight
469.94 g/mol
Drug class
Second-generation irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor
Mechanism of action
Irreversibly inhibits EGFR/HER1, HER2 and HER4 kinase activity and selected activating EGFR mutations, blocking receptor-mediated downstream signalling and tumour-cell proliferation.
Indications / reported uses
  • First-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutation, as detected by an approved test under the US product indication

Sources: US DailyMed — VIZIMPRO (dacomitinib) · FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Second-generation irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor

Mechanism of action

Irreversibly inhibits EGFR/HER1, HER2 and HER4 kinase activity and selected activating EGFR mutations, blocking receptor-mediated downstream signalling and tumour-cell proliferation.

General use cases

  • First-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutation, as detected by an approved test under the US product indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Dacomitinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dacomitinib Permitted Daily Exposure (PDE) report (the Dacomitinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dacomitinib Occupational Exposure Limit (OEL) report (the Dacomitinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.